Growing incidence of cancer creates demand for CAR T-Cell Market Therapy

DataM Intelligence 13 June, 2019
Tallinn, US

DataM Intelligence’s latest market report titled ‘Global CAR-T Cell Therapy Market– Size, Share and Forecast (2019-2026)’ reflects the size, scope, industry dynamics, major firms and future trends in this market.

Global CAR-T Cell Therapy Market Dynamics

The global market for the CAR-T Cell Therapy Market is primarily driven by the growing prevalence of cancer coupled with high demand for an effective treatment for cancer. According to the World Health Organization, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018.
Source- http://dmi-cms.herokuapp.com/research-reports/car-t-cell-therapy-market

Moreover, technological advancements for the reliable treatment of cancer, increasing investments in R&D by crucial market players, governmental initiatives on treatment and research and the growing number of people with immune to chemotherapy and radiations are expected to boost the market growth.

Global CAR-T Cell Therapy Market Segmentation

By Target Antigen- the market is segmented into CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRV III, and others. CD 19 antigens hold a significant market share as they are the most common target have shown remarkable success in a range of blood cancers.

Moreover, the growing prevalence of acute lymphoblastic leukemia in children and adults has strengthened the dominance of CD 19 antigens to be utilized for cancer therapy.

Global CAR-T Cell Therapy Market Geographical Share

North America accounts for the largest share in the global CAR-T Cell Therapy market. This can be mainly attributed to factors such as rising incidents of cancer in the region, and the increasing awareness among the public regarding treatment options. According to the National Cancer Institute, in 2016, an estimated 95,764 people were living with acute lymphocytic leukemia (ALL) in the US.

Global CAR-T Cell Therapy Market Competition

Companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to help them to stand out as strong competitors in the market.
Major Players in the global CAR-T Cell Therapy market include Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.

In February 2019, the UK biotech Cell Medica received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors.

To know more, feel free to download a sample from the following portal -
http://dmi-cms.herokuapp.com/research-reports/car-t-cell-therapy-market

The research report covers the following topics-

1. Global CAR-T Cell Therapy Market -Scope and Methodology
2. Global CAR-T Cell Therapy Market -Key Trends and Developments
3. Global CAR-T Cell Therapy Market – Executive Summary
4. Global CAR-T Cell Therapy Market – Market Dynamics
5. Global CAR-T Cell Therapy Market – Industry Analysis
6. Global CAR-T Cell Therapy Market – By Target Antigen
7. Global CAR-T Cell Therapy Market – By Therapeutic Application
8. Global CAR-T Cell Therapy Market – By Region
9. Global CAR-T Cell Therapy Market – Competitive Landscape
10. Company Profiles
11. Global CAR-T Cell Therapy Market – Premium Insights
12. Global CAR-T Cell Therapy Market – DataM

1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and, Automation among others.

This release was published on openPR.